You need to enable JavaScript to run this app.
Draft guidance: New options for submitting expedited safety reports for IND-exempt BA/BE studies
Regulatory News
Mary Ellen Schneider
Compliance
North America
Pharmaceuticals
Regulatory NewsMary Ellen Schneider
ComplianceNorth AmericaPharmaceuticalsRegulatory NewsMary Ellen SchneiderComplianceNorth AmericaPharmaceuticals